[Venous thromboembolism and breast cancer].

[1]  S. Middeldorp,et al.  American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing , 2023, Blood advances.

[2]  A. Khorana,et al.  Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Mandalà,et al.  Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline†. , 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  H. Al‐Samkari,et al.  Cyclin-dependent kinase 4/6 inhibitor-associated thromboembolism: a critical evaluation of the current evidence. , 2022, Journal of thrombosis and haemostasis : JTH.

[5]  S. Wander,et al.  Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer , 2022, Cancer.

[6]  J. Douketis,et al.  2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 , 2022, The Lancet Oncology.

[7]  N. Magné,et al.  Venous thromboembolism and radiation therapy: The final radiation‐induced thrombosis study analysis , 2022, Cancer medicine.

[8]  P. Fontana,et al.  Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort , 2022, Blood advances.

[9]  F. Pomero,et al.  Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta-analysis. , 2021, Thrombosis research.

[10]  T. Wun,et al.  The incidence of cancer-associated thrombosis is increasing over time , 2021, Blood advances.

[11]  A. Kaempf,et al.  CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice , 2021, European journal of haematology.

[12]  K. Bhaskaran,et al.  Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors , 2020, Heart.

[13]  E. Horváth-Puhó,et al.  Venous thromboembolism in cancer patients: a population-based cohort study. , 2020, Blood.

[14]  A. Giobbie-Hurder,et al.  Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial , 2020, Breast Cancer Research and Treatment.

[15]  P. Neven,et al.  Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Díez-Pérez,et al.  Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study , 2020, Therapeutic advances in medical oncology.

[17]  P. Fasching,et al.  Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. , 2019, The New England journal of medicine.

[18]  A. Khorana,et al.  Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta‐analysis , 2019, Journal of thrombosis and haemostasis : JTH.

[19]  P. Neven,et al.  The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 , 2019, JAMA oncology.

[20]  L. Chow,et al.  Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. , 2019, The New England journal of medicine.

[21]  A. Khorana,et al.  Venous thromboembolism in breast cancer patients receiving cyclin‐dependent kinase inhibitors , 2019, Journal of thrombosis and haemostasis : JTH.

[22]  D. Radojkovic,et al.  Breast cancer and recurrent thrombosis — Results from prospective single center study , 2019, The breast journal.

[23]  P. Wells,et al.  Apixaban to Prevent Venous Thromboembolism in Patients with Cancer , 2019, The New England journal of medicine.

[24]  A. Khorana,et al.  Rivaroxaban for Thromboprophylaxis in High‐Risk Ambulatory Patients with Cancer , 2019, The New England journal of medicine.

[25]  J. Griggs,et al.  Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Chlebowski,et al.  Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors , 2019, Breast Cancer Research and Treatment.

[27]  S. Lai,et al.  Correlation of the tamoxifen use with the increased risk of deep vein thrombosis and pulmonary embolism in elderly women with breast cancer , 2018, Medicine.

[28]  S. Loi,et al.  Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer , 2018, The New England journal of medicine.

[29]  K. Czene,et al.  Time‐dependent risk and predictors of venous thromboembolism in breast cancer patients: A population‐based cohort study , 2017, Cancer.

[30]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[31]  A. Walker,et al.  When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data. , 2016, Blood.

[32]  A. Giobbie-Hurder,et al.  Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. , 2014, The New England journal of medicine.

[33]  D. Cescon,et al.  Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis , 2014, PloS one.

[34]  S. Braekkan,et al.  Epidemiology of cancer-associated venous thrombosis. , 2013, Blood.

[35]  A. Onitilo,et al.  Relationship between Factor V Leiden mutation and venous thromboembolism in patients with breast cancer treated with tamoxifen. , 2013, Thrombosis research.

[36]  H. Earl,et al.  aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Walker,et al.  Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. , 2013, European journal of cancer.

[38]  Ming-Feng Hou,et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.

[39]  A. Onitilo,et al.  Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience. , 2012, Thrombosis research.

[40]  P. Lønning,et al.  Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  D. Heigener,et al.  Low-Molecular-Weight Heparin Versus Placebo for the Prevention of Venous Thromboembolism in Metastatic Breast Cancer or Stage III/IV Lung Cancer , 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[42]  G. Hortobagyi,et al.  Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  A. Ocaña,et al.  Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. , 2011, Journal of the National Cancer Institute.

[44]  N. Akar,et al.  Factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms and the risk of tamoxifen-associated thromboembolism in breast cancer patients. , 2011, Thrombosis research.

[45]  István Láng,et al.  Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  E. Winer,et al.  Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. , 2010, Journal of the National Cancer Institute.

[47]  Niveen Abotouk,et al.  Switching to letrozole versus continued tamoxifen therapy in treatment of postmenopausal women with early breast cancer. , 2010, Journal of the Egyptian National Cancer Institute.

[48]  T. Nokes,et al.  Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics , 2009, Thrombosis and Haemostasis.

[49]  H. Sørensen,et al.  Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism , 2009, Cancer.

[50]  S. Barni,et al.  Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. , 2009, The Lancet. Oncology.

[51]  R. Stuart-Harris,et al.  Risk of venous thromboembolism in patients receiving adjuvant chemotherapy with 5‐fluorouracil, epirubicin and cyclophosphamide for early breast cancer , 2009 .

[52]  Gary H Lyman,et al.  Development and validation of a predictive model for chemotherapy-associated thrombosis. , 2008, Blood.

[53]  I. Zuna,et al.  Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  P. Lønning,et al.  Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial , 2007, The Lancet.

[55]  J. Forbes,et al.  Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  J. Garber,et al.  Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. , 2006, Journal of the National Cancer Institute.

[57]  D. Amadori,et al.  Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  S. Singletary,et al.  Incidence and Prevention of Venous Thromboembolism in Patients Undergoing Breast Cancer Surgery and Treated According to Clinical Pathways , 2006, Annals of surgery.

[59]  J. Forbes,et al.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.

[60]  Michael Gnant,et al.  Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial , 2005, The Lancet.

[61]  J. Cuzick,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[62]  J. Cuzick,et al.  Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  F. Alexander,et al.  Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial , 1995, BMJ.

[64]  H. Johansson,et al.  Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. , 1995, Journal of the National Cancer Institute.

[65]  J. Hirsh,et al.  Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer , 1994, The Lancet.

[66]  R. Gray,et al.  Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  C. Redmond,et al.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. , 1989, The New England journal of medicine.

[68]  D. Radojkovic,et al.  Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study. , 2015, European journal of internal medicine.

[69]  M. Di Nisio,et al.  Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. , 2014, The Cochrane database of systematic reviews.

[70]  N. Akar,et al.  PT G20210A, factors V G1691A and 1299 His-Arg mutations and tamoxifen-associated thromboembolism in patients with breast cancer. , 2003, Thrombosis research.

[71]  R. Gray,et al.  Tamoxifen versus placebo: double-blind adjuvant trial in elderly women with stage II breast cancer. , 1986, NCI monographs : a publication of the National Cancer Institute.